Commentary: Efficacy of prenatal treatment for toxoplasmosis: a possibility that cannot be ruled out.
Thulliez
P
P
Laboratoire de la Toxoplasmose, Institut de Puériculture, Paris, France.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D018942:Macrolides; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000188:drug therapy; D011295:Prenatal Care; D014125:Toxoplasmosis, Congenital / Q000188:drug therapy / Q000635:transmission*
D000900:Anti-Bacterial Agents; D000981:Antiprotozoal Agents; D018942:Macrolides